Optimizing surgical performance
Over recent decades, robots have transformed cancer surgery. However, in spite of the technological advances in robotic platforms, surgeons still remain completely dependent on their sight to detect cancer intra-operatively. As a result, surgeons often leave cancer behind or remove more healthy tissue than needed. Residual disease increases the need for further drug treatment, radiotherapy, and surgery. Similarly, removing healthy, functional tissue increases post-surgical complications and escalates healthcare costs.
At Lightpoint, we are optimizing the performance of robotic cancer surgery, by developing miniaturized imaging and sensing tools to accurately detect cancer intra-operatively during robot-assisted surgery. The aims of the tools are to aid surgical decision making, improve patient outcomes and save costs for healthcare system.
Find out more about SENSEI® on our product website
Management team
Dr David Tuch, CEO & Founder
Claire Woodthorpe, VP Europe & COO
Claire Woodthorpe, VP Europe & COO
David has more than a decade of experience in the medical imaging and pharmaceutical sectors. Previously, he was Head of Research Alliances at GE Healthcare and Head of Clinical Imaging at Novartis. Before joining industry, David served on the faculty of Harvard Medical School and Massachusetts General Hospital, Department of Radiology. He holds a PhD from MIT and Harvard Medical School, and a BA from the University of Chicago.
Claire Woodthorpe, VP Europe & COO
Claire Woodthorpe, VP Europe & COO
Claire Woodthorpe, VP Europe & COO
Claire Woodthorpe has more than ten years of experience in commercial operations, including six years in the medical device industry. Before joining Lightpoint she held board level positions in technology companies specializing in research and development. Claire is a CTA-qualified accountant. She holds an LLB with Honors in Law with Accounting and Finance from the University of Liverpool.
Simon McCoy, Finance Director
Claire Woodthorpe, VP Europe & COO
Simon McCoy, Finance Director
Simon McCoy ACA has 30 years’ experience in blue chip international organizations in the life science, healthcare, and leisure sectors. As an experienced finance leader, his diverse experience includes business strategy, business analytics, pricing, M&A activity, process improvement and streamlining, and financial management. Simon has a BA with Honors in Geography from the University of Exeter.
Board of directors
.jpg/:/cr=t:0%25,l:0%25,w:100%25,h:100%25/rs=w:365,h:365,cg:true/qt=q:1/fx-gs)
Dr David Tuch, Chairman & CEO
Dr David Tuch, Chairman & CEO
Dr David Tuch, Chairman & CEO
David Ford, MBA
Dr David Tuch, Chairman & CEO
Dr David Tuch, Chairman & CEO
David has more than 20 years experience in the medical device industry. Formerly the Executive Director of BSI Group, he was responsible for the worldwide Healthcare and Testing activity for the British Standards Institution. David is currently CEO at Ingenica Solutions and a Non-Executive Director at NHS TrusTECH. David has represented the United Kingdom at the World Health Organization, the FDA and the European Commission in developing policy for medical devices and medical device regulation. David was trained at St. Mary’s Hospital Medical School, London and at Brunel University, and holds an MBA from INSEAD.
Nadim Yared
Dr David Tuch, Chairman & CEO
Elizabeth Usher, MBA
Nadim is the President and Chief Executive Officer of CVRx. He has previously served as Vice President and General Manager of Medtronic Navigation, the leading global supplier of integrated image-guided surgery products. He also worked at GE Medical for 10-years, where he was Vice President of Global Marketing for the OEC Medical Systems and Vice President and General Manager of GE’s European X-ray business based in Paris. Nadim has an engineering degree from Ecole Nationale Supérieure des Télécommunications, and an MBA from INSEAD, France.
Elizabeth Usher, MBA
Elizabeth Usher, MBA
Elizabeth Usher, MBA
Elizabeth has more than 20 years of experience in the medical device industry. She is currently the Executive Director & CEO of the American Academy of Dermatology (AAD), and was previously the Chief Marketing, Sales, and Communications Officer for the College of American Pathologists (CAP). Prior to joining CAP, she held executive leadership positions at GE Healthcare and Amersham Health. She has an MBA in International Business from Thunderbird School of Global Management and a Bachelor of Science degree from Georgia Institute of Technology.
Martin Jamieson
Elizabeth Usher, MBA
Martin Jamieson
After completing his early career in the pharmaceutical industry at Wyeth and 3M, Martin worked for Smiths Medical. Over 16 years he took on increasingly senior Managing Director roles, finally as Managing Director Smiths Medical International. Latterly, Martin has served as CEO of Rayner Surgical and CEO & Chairman of Nextism Plc, a medical device company focused on improving rehabilitation for stroke patients using non-invasive brain stimulation. Martin currently works with a number of private equity houses and is a Non-Executive Director of a large NHS Foundation Trust Hospital and multiple medtech SMEs.